Study type: Human research · Status: Verified against declared source

The Use of IV Vasoactive Intestinal Chemical sequence (Aviptadil) in Patients With Critical COVID-19 Respiratory Failure: Results of a 60-Day Randomized Controlled Trial.

Critical care medicine · 2022

Study scale: Participants were randomized 2:1 to receive 3 days of IV Aviptadil or placebo.

Abstract only: Open source record

Product or molecular entity relationships

VIP: Exact entity relationship. Legacy citation custody associates this source with the catalog record; no product-relevance conclusion is implied.

Plain-language verified summary

Question

Respiratory failure is a lethal complication of COVID-19 that has remained resistant to drug therapy.

Methods

Aviptadil, a synthetic form of vasoactive intestinal peptide (VIP), has been granted U.S.

Scale or participants

Participants were randomized 2:1 to receive 3 days of IV Aviptadil or placebo.

Key findings

Respiratory failure is a lethal complication of COVID-19 that has remained resistant to drug therapy.

Limitations and uncertainty

The primary end point (alive and free from respiratory failure at day 60) did not reach statistical significance (odds ratio [OR], 1.6; 95% CI, 0.86–3.11) for patients treated with Aviptadil when controlling for baseline ventilation status as prespecified in the protocol.

Verified against declared source. Verification is limited to the declared source and review scope. It does not mean independent replication or establish efficacy, safety, or suitability.